Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
JNGHFDrugs in Pipeline
178
Phase 3 Programs
94
Upcoming Catalysts
37
Next Catalyst
Feb 15, 2026
7dMarket Overview
Stock performance and market intelligence
37 upcoming, 1 past
SHR-A1811 Phase 3 Results Expected
Primary completion for SHR-A1811 trial (NCT06430437) in Non-Small Cell Lung Cancer With HER2- Mutations
SourceInsulin Degludec Phase 2 Results Expected
Primary completion for Insulin Degludec trial (NCT07018453) in Type 2 Diabetes Mellitus
SourceSHR-3167 Phase 2 Results Expected
Primary completion for SHR-3167 trial (NCT07018453) in Type 2 Diabetes Mellitus
SourceHRS-8427 Phase 2 Results Expected
Primary completion for HRS-8427 trial (NCT06841731) in Hospital-acquired Bacterial Pneumonia (HABP)
SourceMeropenem Phase 2 Results Expected
Primary completion for Meropenem trial (NCT06841731) in Hospital-acquired Bacterial Pneumonia (HABP)
SourceSHR-A1811 Injection Phase 2 Results Expected
Primary completion for SHR-A1811 Injection trial (NCT07051486) in Recurrent or Metastatic Cervical Cancer
SourceCamrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin Phase 3 Results Expected
Primary completion for Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin trial (NCT06430437) in Non-Small Cell Lung Cancer With HER2- Mutations
SourceSHR0302Base gel Phase 2 Results Expected
Primary completion for SHR0302Base gel trial (NCT06790862) in Vitiligo
SourceSHR-A1904 Phase 2 Results Expected
Primary completion for SHR-A1904 trial (NCT05277168) in Advanced Solid Tumors
SourceHRS-9190 Phase 2 Results Expected
Primary completion for HRS-9190 trial (NCT07252921) in Neuromuscular Blockade
SourceRemimazolam Tosilate for injection Phase 2 Results Expected
Primary completion for Remimazolam Tosilate for injection trial (NCT07036419) in Operative Sedation of Pediatric
SourceInsulin glargine Phase 2 Results Expected
Primary completion for Insulin glargine trial (NCT06688123) in Type 2 Diabetes
SourceSHR-3167 Phase 2 Results Expected
Primary completion for SHR-3167 trial (NCT06688123) in Type 2 Diabetes
SourceApatinib Mesylate Phase 3 Results Expected
Primary completion for Apatinib Mesylate trial (NCT04342910) in Gastric Cancer
SourceJSKN003 Phase 3 Results Expected
Primary completion for JSKN003 trial (NCT06079983) in Breast Cancer
SourceCapecitabine tablets Phase 3 Results Expected
Primary completion for Capecitabine tablets trial (NCT06079983) in Breast Cancer
Sourcecamrelizumab Phase 3 Results Expected
Primary completion for camrelizumab trial (NCT04342910) in Gastric Cancer
SourceHRS-6768 Phase 2 Results Expected
Primary completion for HRS-6768 trial (NCT06925581) in Advanced Solid Tumors
SourceSHR2554; Chidamide analog tablets Phase 3 Results Expected
Primary completion for SHR2554; Chidamide analog tablets trial (NCT06122389) in Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
SourceSHR7280 tablets Phase 3 Results Expected
Primary completion for SHR7280 tablets trial (NCT05442827) in Uterine Fibroids With Menorrhagia
SourceHRS-1167 tablets Phase 2 Results Expected
Primary completion for HRS-1167 tablets trial (NCT06568094) in Prostate Cancer
SourceSTSA-1301 subcutaneous injection Phase 2 Results Expected
Primary completion for STSA-1301 subcutaneous injection trial (NCT06929299) in Primary Immune Thrombocytopenia (ITP)
SourceSHR- A1811 Phase 2 Results Expected
Primary completion for SHR- A1811 trial (NCT05896020) in Gynaecological Malignancies
SourceHRS-5041 tablets Phase 2 Results Expected
Primary completion for HRS-5041 tablets trial (NCT06568094) in Prostate Cancer
SourceJSKN003 Phase 2 Results Expected
Primary completion for JSKN003 trial (NCT05744427) in Advanced Solid Tumor
SourceTACE+Camrelizumab+Apatinib mesylate Phase 3 Results Expected
Primary completion for TACE+Camrelizumab+Apatinib mesylate trial (NCT05320692) in Hepatocellular Carcinoma
SourceRivoceranib (Apatinib) Phase 3 Results Expected
Primary completion for Rivoceranib (Apatinib) trial (NCT04639180) in Hepatocellular Carcinoma (HCC)
SourceCamrelizumab Phase 3 Results Expected
Primary completion for Camrelizumab trial (NCT04639180) in Hepatocellular Carcinoma (HCC)
SourceSTSP-0601 for Injection Phase 3 Results Expected
Primary completion for STSP-0601 for Injection trial (NCT06922045) in Hemophilia
SourceSHR6390 Phase 3 Results Expected
Primary completion for SHR6390 trial (NCT04842617) in Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer
SourceSHR-A1811 combined with Pyrotinib. Phase 2 Results Expected
Primary completion for SHR-A1811 combined with Pyrotinib. trial (NCT06015048) in HER2-expressing Advanced Solid Tumors
SourceLutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide Phase 3 Results Expected
Primary completion for Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide trial (NCT05884255) in Advanced Gastroenteropancreatic Neuroendocrine Tumor
SourceVC004 Capsules Phase 3 Results Expected
Primary completion for VC004 Capsules trial (NCT06658353) in Locally Advanced Solid Tumor
SourceVicagrel Phase 3 Results Expected
Primary completion for Vicagrel trial (NCT06577519) in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
SourcePyrotinib in combination with Capecitabine. Phase 3 Results Expected
Primary completion for Pyrotinib in combination with Capecitabine. trial (NCT05424835) in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
SourceFuzuloparib , Abiraterone acetate and Prednisone Phase 3 Results Expected
Primary completion for Fuzuloparib , Abiraterone acetate and Prednisone trial (NCT04691804) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
SourceSHR-A1811 Phase 3 Results Expected
Primary completion for SHR-A1811 trial (NCT05424835) in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
X0002 Spray
KNEE OSTEOARTHRITIS
SIM0270
Locally Advanced or Metastatic Breast Cancer
Apatinib Mesylate
Gastric Cancer
paclitaxel
Advanced Esophageal Cancer
Noiiglutide Injection
Type 2 Diabetes
SIM0417
COVID-19
Rezvilutamide Tablets
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
SHR6390
Advanced Breast Cancer
Famitinib
Colorectal Cancer Metastatic
VC005 tablets
Moderate to Severe Atopic Dermatitis
JSKN003
Advanced Solid Tumor
Propofol
Sedation
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
First-line Treatment of Advanced Pancreatic Cancer
Daridorexant
Insomnia Disorder
HR17031 injection
Adult Patients With Type 2 Diabetes
HRS-8427
Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
SHR0410 Injection
Pain
SHR3680
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
SHR8554 Injection
Pain
Lansoprazole
Reflux Esophagitis
BD0801
Ovarian Cancer
DZD8586
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Sulijia
Advanced Non-small Cell Lung Cancer
Hetrombopag Olamine
Idiopathic Thrombocytopenic Purpura
Capecitabine
Gastric Cancer
SHR4640 dose1
Gout
Hetrombopag Olamine+Standard Therapy
Severe Aplastic Anemia
Insulin Glargine
Type 2 Diabetes Mellitus
Pyrotinib in combination with Capecitabine.
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Herombopag tablets
Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Non-Small Cell Lung Cancer With HER2- Mutations
Fluzoparib capsules
Ovarian Cancer
SHR8058 eye drops
Treatment of Dry Eye Disease With Meibomian Gland Dysfunction
SHR4640
Gout
Drug: Pegylated rhG-CSF: 100µg/kg
Breast Cancer
Hetrombopag
Chemotherapy-Induced Thrombocytopenia
pyrotinib
Non Small Cell Lung
SHR0302
Rheumatoid Arthritis
Paclitaxel Injection
Ovarian Cancer
Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
Breast Cancer
Carboplatin
Lung Neoplasms
Morphine
Pain
Remimazolam Tosilate
Sedation
ASK120067
Locally Advanced or Metastatic NSCLC
KN046
Advanced Pancreatic Ductal Adenocarcinoma
VC005 low dose group
Moderate to Severe Atopic Dermatitis
SHR8028 eye drops
Dry Eye Disease
FRSW117
Severe Hemophilia A
Tanreqing capsule
Novel Coronavirus Pneumonia
Irinotecan
Esophageal Carcinoma
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate
First-line Treatment of Metastatic Pancreatic Cancer
Shenbai Granules
Gastroenterology
SHR-A1811 for Injection
Early-stage or Locally Advanced HER2-positive Breast Cancer
SHR-A1811
Advanced Non-small Cell Lung Cancer
Irinotecan liposome、5-Fluorouracil、Leucovorin
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Vicagrel
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
XLJDOD compound granule
Colon Cancer
STSP-0601 for Injection
Hemophilia
SHR-1210
Gastric Cancer
Sorafenib
Locally Advanced or Metastatic and Unresectable HCC
SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin
Non-Small-Cell Lung Cancer
SHR-1209
Primary Hypercholesterolemia
INS068 injection
Type 2 Diabetes
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Rivoceranib (Apatinib)
Hepatocellular Carcinoma (HCC)
Camrelizumab Plus Chemotherapy
Triple Negative Breast Cancer
Camrelizumab
Solid Tumor
BP102, paclitaxel, carboplatin
Non-small Cell Lung Cancer(NSCLC)
Paracetamol injection
Post-operative Analgesia
SHR-A1811 Injection
Advanced Gastric Cancer
ENDOSTAR，cisplatin
Malignant Pleural Effusion
Nalbuphine Hydrochloride Injection
Postoperative Analgesia
Suvemcitug injection, trifluridine/tipiracil tablets
Refractory Metastatic Colorectal Cancer
Zanamivir
Influenza A Virus Infection
SHR7280 tablets
Female Subjects Undergoing COH in ART to Prevent Early Ovulation
Recombinant two-component COVID-19 vaccine (CHO cell)
COVID-19
Fuzuloparib , Abiraterone acetate and Prednisone
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
X842
Reflux Esophagitis
Docetaxel
Non-squamous NSCLC
Propofol Medium and Long Chain Fat Emulsion Injection
Sedation in the ICU
SHR7280；Ganirelix Acetate Injection simulant
Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
TACE+Camrelizumab+Apatinib mesylate
Hepatocellular Carcinoma
SHR2554; Chidamide analog tablets
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Almonertinib
Non-small Cell Lung Cancer
SHR-A1811 Injection ； Pertuzumab Injection
HER2-PositiveRecurrent or Metastatic Breast Cancer
68Ga-DOTATOC
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Apatinib
Carcinoma, Hepatocellular
Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Trilaciclib, carboplatin, etoposide，or Topotecan
Extensive-stage Small-cell Lung Cancer
Capecitabine tablets
Breast Cancer
Compound Edaravone Injection
Acute Ischemic Stroke
sunvozertinib
Non-Small Cell Lung Cancer
VC004 Capsules
Locally Advanced Solid Tumor
camrelizumab； famitinib malate
Cervical Cancer
SHR-1703
Asthma With Eosinophilic Phenotype
SHR0302 Tablets
Non-segmental Vitiligo
APL-1202 treatment
Non-muscle Invasive Bladder Cancer
RSS0343 Tabella
Adolescent Asthma
SHR-1020
Recurrent or Metastatic Cervical Cancer
KN026 combination
HER2-positive Solid Tumors
mFOLFIRINOX
Advanced Pancreatic Cancer
benzbromarone
Hyperuricemia
NH102
Major Depressive Disorder (MDD)
JSKN016
Inoperable Locally Advanced HER2-Negative Breast Cancer
TSL-1502 capsules(low dose)
Breast Cancer Metastatic
DZD6008
Non-Small Cell Lung Cancer
SHR2554/CHOP
Peripheral T-cell Lymphoma
SP2086(50 mg q.d.)/Metformin
Type 2 Diabetes
KN019, 5mg/kg
Rheumatoid Arthritis
RY_SW01 cell injection
Lupus Nephritis
HR18042
Moderate to Severe Acute Pain
KN026 10 mg/kg QW
Gastric/Gastroesophageal Junction Cancer
Nab-paclitaxel
Triple-negative Breast Cancer
Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets
Metastatic Castration Resistant Prostate Cancer
Palonosetron
Cancer
Basic treatment
Systemic Sclerosis
SHR-1701
Pancreatic Cancer
SHR117887
Type 2 Diabetes
Adebrelimab
Advanced KRAS G12D Mutant Solid Tumors
FOLFOX4
Advanced Primary Liver Cancer
STSA-1301 subcutaneous injection
Primary Immune Thrombocytopenia (ITP)
SSD8432 dose 1/Ritonavir
COVID-19 Patients
HS-20004
Diabetes Mellitus, Type 2
SS109
Male
Pegylated rhG-CSF 100μg/kg
Breast Cancer
HRS-9190
Neuromuscular Blockade
Abiraterone Acetate Tablets (I)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
HRS-1167 tablets
Prostate Cancer
HRS-4642
Advanced Solid Tumors
HRS4800 tablets
Pain
HRS-6209 Capsules
Breast Cancer
FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin
Lung Cancer
HRS-5041 tablets
Prostate Cancer
Fluzoparib+Apatinib
Relapsed Ovarian Cancer
Vicagrel 5mg
Coronary Artery Disease
Bendamustine hydrochloride injection
Chronic Lymphocytic Leukemia
SHR-A1811 combined with Pyrotinib.
HER2-expressing Advanced Solid Tumors
Fluzoparib
Small Cell Lung Cancer
HRG2010(I)
Parkinson's Disease
Sunitinib
Renal Cell Cancer
high dose KYG0395
Primary Dysmenorrhea
Tofacitinib Citrate Tablets
Active Ankylosing Spondylitis
VC005 groups
Atopic Dermatitis
HR021618
Pain After Abdominal Surgery
HS-10375
Advanced or Metastatic NSCLC
HS-10365 capsules
Nonsmall Cell Lung Cancer
HS-20094
Type 2 Diabetes
Mesenchymal Stem Cells (MSCs)
Chronic Radiation Proctitis
SHR7280
Endometriosis
50 mg SP2086
Type 2 Diabetes
SHR 1210+apatinib
Hepatocellular Carcinoma
SHR-3167
Type 2 Diabetes
Meplazumab for Injection
Malaria
HRS-4508 tablet
Solid Tumor
SHR0302Base gel
Vitiligo
HRS-6209 in Combination with Fulvestrant
Advanced Unresectable or Metastatic Breast Cancer
SHR-A1904
Advanced Solid Tumors
HRS-6768
Advanced Solid Tumors
SHR- A1811
Gynaecological Malignancies
Endostar
Malignant Pleural Effusion
ACC017+FTC/TAF
Infection, Human Immunodeficiency Virus
ASKB589 Injection
Malignant Solid Tumor
Human TH-SC01 cell injection
Perianal Fistula
Meropenem
Hospital-acquired Bacterial Pneumonia (HABP)
KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
Advanced Non-small Cell Lung Cancer
COVID-19 Vaccine (Vero Cell), Inactivated
COVID-19
SHR-1314
Moderate-to-severe Chronic Plaque Psoriasis
HR020602 injection
Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)
HRS-6213
Patients With Solid Tumors
Camrelizumab、Rivoceranib
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Edaravone Injection
Acute Ischemic Stroke
Venetoclax
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
SHR2554; SHR-A2102
Locally Advanced or Metastatic Non-small Cell Lung Cancer
FH-006
Malignant Solid Tumor
Remimazolam Tosilate for injection
Operative Sedation of Pediatric
Insulin Degludec
Type 2 Diabetes
HR19042 Capsules
Autoimmune Hepatitis
Propofol Injection.
Local Anesthesia Assisted Sedation
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
X0002 Spray | Phase 3 | KNEE OSTEOARTHRITIS | - |
SIM0270 | Phase 3 | Locally Advanced or Metastatic Breast Cancer | - |
Apatinib Mesylate | Phase 3 | Gastric Cancer | - |
paclitaxel | Phase 3 | Advanced Esophageal Cancer | - |
Noiiglutide Injection | Phase 3 | Type 2 Diabetes | - |
SIM0417 | Phase 3 | COVID-19 | - |
Rezvilutamide Tablets | Phase 3 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | - |
SHR6390 | Phase 3 | Advanced Breast Cancer | - |
Famitinib | Phase 3 | Colorectal Cancer Metastatic | - |
VC005 tablets | Phase 3 | Moderate to Severe Atopic Dermatitis | - |
JSKN003 | Phase 3 | Advanced Solid Tumor | - |
Propofol | Phase 3 | Sedation | - |
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate | Phase 3 | First-line Treatment of Advanced Pancreatic Cancer | - |
Daridorexant | Phase 3 | Insomnia Disorder | - |
HR17031 injection | Phase 3 | Adult Patients With Type 2 Diabetes | - |
HRS-8427 | Phase 3 | Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) | - |
SHR0410 Injection | Phase 3 | Pain | - |
SHR3680 | Phase 3 | Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | - |
SHR8554 Injection | Phase 3 | Pain | - |
Lansoprazole | Phase 3 | Reflux Esophagitis | - |
BD0801 | Phase 3 | Ovarian Cancer | - |
DZD8586 | Phase 3 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | - |
Sulijia | Phase 3 | Advanced Non-small Cell Lung Cancer | - |
Hetrombopag Olamine | Phase 3 | Idiopathic Thrombocytopenic Purpura | - |
Capecitabine | Phase 3 | Gastric Cancer | - |
SHR4640 dose1 | Phase 3 | Gout | - |
Hetrombopag Olamine+Standard Therapy | Phase 3 | Severe Aplastic Anemia | - |
Insulin Glargine | Phase 3 | Type 2 Diabetes Mellitus | - |
Pyrotinib in combination with Capecitabine. | Phase 3 | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | - |
Herombopag tablets | Phase 3 | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | - |
Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin | Phase 3 | Non-Small Cell Lung Cancer With HER2- Mutations | - |
Fluzoparib capsules | Phase 3 | Ovarian Cancer | - |
SHR8058 eye drops | Phase 3 | Treatment of Dry Eye Disease With Meibomian Gland Dysfunction | - |
SHR4640 | Phase 3 | Gout | - |
Drug: Pegylated rhG-CSF: 100µg/kg | Phase 3 | Breast Cancer | - |
Hetrombopag | Phase 3 | Chemotherapy-Induced Thrombocytopenia | - |
pyrotinib | Phase 3 | Non Small Cell Lung | - |
SHR0302 | Phase 3 | Rheumatoid Arthritis | - |
Paclitaxel Injection | Phase 3 | Ovarian Cancer | - |
Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel | Phase 3 | Breast Cancer | - |
Carboplatin | Phase 3 | Lung Neoplasms | - |
Morphine | Phase 3 | Pain | - |
Remimazolam Tosilate | Phase 3 | Sedation | - |
ASK120067 | Phase 3 | Locally Advanced or Metastatic NSCLC | - |
KN046 | Phase 3 | Advanced Pancreatic Ductal Adenocarcinoma | - |
VC005 low dose group | Phase 3 | Moderate to Severe Atopic Dermatitis | - |
SHR8028 eye drops | Phase 3 | Dry Eye Disease | - |
FRSW117 | Phase 3 | Severe Hemophilia A | - |
Tanreqing capsule | Phase 3 | Novel Coronavirus Pneumonia | - |
Irinotecan | Phase 3 | Esophageal Carcinoma | - |
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate | Phase 3 | First-line Treatment of Metastatic Pancreatic Cancer | - |
Shenbai Granules | Phase 3 | Gastroenterology | - |
SHR-A1811 for Injection | Phase 3 | Early-stage or Locally Advanced HER2-positive Breast Cancer | - |
SHR-A1811 | Phase 3 | Advanced Non-small Cell Lung Cancer | - |
Irinotecan liposome、5-Fluorouracil、Leucovorin | Phase 3 | Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy | - |
Vicagrel | Phase 3 | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | - |
XLJDOD compound granule | Phase 3 | Colon Cancer | - |
STSP-0601 for Injection | Phase 3 | Hemophilia | - |
SHR-1210 | Phase 3 | Gastric Cancer | - |
Sorafenib | Phase 3 | Locally Advanced or Metastatic and Unresectable HCC | - |
SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin | Phase 3 | Non-Small-Cell Lung Cancer | - |
SHR-1209 | Phase 3 | Primary Hypercholesterolemia | - |
INS068 injection | Phase 3 | Type 2 Diabetes | - |
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor | - |
Rivoceranib (Apatinib) | Phase 3 | Hepatocellular Carcinoma (HCC) | - |
Camrelizumab Plus Chemotherapy | Phase 3 | Triple Negative Breast Cancer | - |
Camrelizumab | Phase 3 | Solid Tumor | - |
BP102, paclitaxel, carboplatin | Phase 3 | Non-small Cell Lung Cancer(NSCLC) | - |
Paracetamol injection | Phase 3 | Post-operative Analgesia | - |
SHR-A1811 Injection | Phase 3 | Advanced Gastric Cancer | - |
ENDOSTAR，cisplatin | Phase 3 | Malignant Pleural Effusion | - |
Nalbuphine Hydrochloride Injection | Phase 3 | Postoperative Analgesia | - |
Suvemcitug injection, trifluridine/tipiracil tablets | Phase 3 | Refractory Metastatic Colorectal Cancer | - |
Zanamivir | Phase 3 | Influenza A Virus Infection | - |
SHR7280 tablets | Phase 3 | Female Subjects Undergoing COH in ART to Prevent Early Ovulation | - |
Recombinant two-component COVID-19 vaccine (CHO cell) | Phase 3 | COVID-19 | - |
Fuzuloparib , Abiraterone acetate and Prednisone | Phase 3 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | - |
X842 | Phase 3 | Reflux Esophagitis | - |
Docetaxel | Phase 3 | Non-squamous NSCLC | - |
Propofol Medium and Long Chain Fat Emulsion Injection | Phase 3 | Sedation in the ICU | - |
SHR7280；Ganirelix Acetate Injection simulant | Phase 3 | Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation | - |
TACE+Camrelizumab+Apatinib mesylate | Phase 3 | Hepatocellular Carcinoma | - |
SHR2554; Chidamide analog tablets | Phase 3 | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | - |
Almonertinib | Phase 3 | Non-small Cell Lung Cancer | - |
SHR-A1811 Injection ； Pertuzumab Injection | Phase 3 | HER2-PositiveRecurrent or Metastatic Breast Cancer | - |
68Ga-DOTATOC | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor | - |
Apatinib | Phase 3 | Carcinoma, Hepatocellular | - |
Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan | Phase 3 | HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | - |
Trilaciclib, carboplatin, etoposide，or Topotecan | Phase 3 | Extensive-stage Small-cell Lung Cancer | - |
Capecitabine tablets | Phase 3 | Breast Cancer | - |
Compound Edaravone Injection | Phase 3 | Acute Ischemic Stroke | - |
sunvozertinib | Phase 3 | Non-Small Cell Lung Cancer | - |
VC004 Capsules | Phase 3 | Locally Advanced Solid Tumor | - |
camrelizumab； famitinib malate | Phase 3 | Cervical Cancer | - |
SHR-1703 | Phase 2 | Asthma With Eosinophilic Phenotype | - |
SHR0302 Tablets | Phase 2 | Non-segmental Vitiligo | - |
APL-1202 treatment | Phase 2 | Non-muscle Invasive Bladder Cancer | - |
RSS0343 Tabella | Phase 2 | Adolescent Asthma | - |
SHR-1020 | Phase 2 | Recurrent or Metastatic Cervical Cancer | - |
KN026 combination | Phase 2 | HER2-positive Solid Tumors | - |
mFOLFIRINOX | Phase 2 | Advanced Pancreatic Cancer | - |
benzbromarone | Phase 2 | Hyperuricemia | - |
NH102 | Phase 2 | Major Depressive Disorder (MDD) | - |
JSKN016 | Phase 2 | Inoperable Locally Advanced HER2-Negative Breast Cancer | - |
TSL-1502 capsules(low dose) | Phase 2 | Breast Cancer Metastatic | - |
DZD6008 | Phase 2 | Non-Small Cell Lung Cancer | - |
SHR2554/CHOP | Phase 2 | Peripheral T-cell Lymphoma | - |
SP2086(50 mg q.d.)/Metformin | Phase 2 | Type 2 Diabetes | - |
KN019, 5mg/kg | Phase 2 | Rheumatoid Arthritis | - |
RY_SW01 cell injection | Phase 2 | Lupus Nephritis | - |
HR18042 | Phase 2 | Moderate to Severe Acute Pain | - |
KN026 10 mg/kg QW | Phase 2 | Gastric/Gastroesophageal Junction Cancer | - |
Nab-paclitaxel | Phase 2 | Triple-negative Breast Cancer | - |
Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets | Phase 2 | Metastatic Castration Resistant Prostate Cancer | - |
Palonosetron | Phase 2 | Cancer | - |
Basic treatment | Phase 2 | Systemic Sclerosis | - |
SHR-1701 | Phase 2 | Pancreatic Cancer | - |
SHR117887 | Phase 2 | Type 2 Diabetes | - |
Adebrelimab | Phase 2 | Advanced KRAS G12D Mutant Solid Tumors | - |
FOLFOX4 | Phase 2 | Advanced Primary Liver Cancer | - |
STSA-1301 subcutaneous injection | Phase 2 | Primary Immune Thrombocytopenia (ITP) | - |
SSD8432 dose 1/Ritonavir | Phase 2 | COVID-19 Patients | - |
HS-20004 | Phase 2 | Diabetes Mellitus, Type 2 | - |
SS109 | Phase 2 | Male | - |
Pegylated rhG-CSF 100μg/kg | Phase 2 | Breast Cancer | - |
HRS-9190 | Phase 2 | Neuromuscular Blockade | - |
Abiraterone Acetate Tablets (I) | Phase 2 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | - |
HRS-1167 tablets | Phase 2 | Prostate Cancer | - |
HRS-4642 | Phase 2 | Advanced Solid Tumors | - |
HRS4800 tablets | Phase 2 | Pain | - |
HRS-6209 Capsules | Phase 2 | Breast Cancer | - |
FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin | Phase 2 | Lung Cancer | - |
HRS-5041 tablets | Phase 2 | Prostate Cancer | - |
Fluzoparib+Apatinib | Phase 2 | Relapsed Ovarian Cancer | - |
Vicagrel 5mg | Phase 2 | Coronary Artery Disease | - |
Bendamustine hydrochloride injection | Phase 2 | Chronic Lymphocytic Leukemia | - |
SHR-A1811 combined with Pyrotinib. | Phase 2 | HER2-expressing Advanced Solid Tumors | - |
Fluzoparib | Phase 2 | Small Cell Lung Cancer | - |
HRG2010(I) | Phase 2 | Parkinson's Disease | - |
Sunitinib | Phase 2 | Renal Cell Cancer | - |
high dose KYG0395 | Phase 2 | Primary Dysmenorrhea | - |
Tofacitinib Citrate Tablets | Phase 2 | Active Ankylosing Spondylitis | - |
VC005 groups | Phase 2 | Atopic Dermatitis | - |
HR021618 | Phase 2 | Pain After Abdominal Surgery | - |
HS-10375 | Phase 2 | Advanced or Metastatic NSCLC | - |
HS-10365 capsules | Phase 2 | Nonsmall Cell Lung Cancer | - |
HS-20094 | Phase 2 | Type 2 Diabetes | - |
Mesenchymal Stem Cells (MSCs) | Phase 2 | Chronic Radiation Proctitis | - |
SHR7280 | Phase 2 | Endometriosis | - |
50 mg SP2086 | Phase 2 | Type 2 Diabetes | - |
SHR 1210+apatinib | Phase 2 | Hepatocellular Carcinoma | - |
SHR-3167 | Phase 2 | Type 2 Diabetes | - |
Meplazumab for Injection | Phase 2 | Malaria | - |
HRS-4508 tablet | Phase 2 | Solid Tumor | - |
SHR0302Base gel | Phase 2 | Vitiligo | - |
HRS-6209 in Combination with Fulvestrant | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - |
SHR-A1904 | Phase 2 | Advanced Solid Tumors | - |
HRS-6768 | Phase 2 | Advanced Solid Tumors | - |
SHR- A1811 | Phase 2 | Gynaecological Malignancies | - |
Endostar | Phase 2 | Malignant Pleural Effusion | - |
ACC017+FTC/TAF | Phase 2 | Infection, Human Immunodeficiency Virus | - |
ASKB589 Injection | Phase 2 | Malignant Solid Tumor | - |
Human TH-SC01 cell injection | Phase 2 | Perianal Fistula | - |
Meropenem | Phase 2 | Hospital-acquired Bacterial Pneumonia (HABP) | - |
KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection) | Phase 2 | Advanced Non-small Cell Lung Cancer | - |
COVID-19 Vaccine (Vero Cell), Inactivated | Phase 2 | COVID-19 | - |
SHR-1314 | Phase 2 | Moderate-to-severe Chronic Plaque Psoriasis | - |
HR020602 injection | Phase 2 | Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol) | - |
HRS-6213 | Phase 2 | Patients With Solid Tumors | - |
Camrelizumab、Rivoceranib | Phase 2 | Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | - |
Edaravone Injection | Phase 2 | Acute Ischemic Stroke | - |
Venetoclax | Phase 2 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | - |
SHR2554; SHR-A2102 | Phase 2 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | - |
FH-006 | Phase 2 | Malignant Solid Tumor | - |
Remimazolam Tosilate for injection | Phase 2 | Operative Sedation of Pediatric | - |
Insulin Degludec | Phase 2 | Type 2 Diabetes | - |
HR19042 Capsules | Phase 2 | Autoimmune Hepatitis | - |
Propofol Injection. | Phase 2 | Local Anesthesia Assisted Sedation | - |
Regulatory & News
Approvals, filings, and latest developments